Identification of doxorubicin and an imine derivative from liquid and solid samples utilizing liquid chromatography

Journal of Liquid Chromatography and Related Technologies

Volumn 29, Issue 15, 2006, Pages 2303-2312

  Bartzatt, Ronald ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Adriamycin; Anthracycline; Anticancer; Doxorubicin; HPLC; Imine

Indexed keywords

ALCOHOLS; AMINES; DERIVATIVES; DISEASE CONTROL; EXTRACTION; MIXTURES; SOLUBILITY; SUGARS;

ADRIAMYCIN; ANTHRACYCLINE; ANTICANCER; DOXORUBICIN; IMINE;

PROTEINS;

ALCOHOL; BUTANOL; DOXORUBICIN; IMINE; METHANOL; METHYL GROUP; PENTANOL; WATER;

AQUEOUS SOLUTION; ARTICLE; COLOR; DRUG SOLUBILITY; DRUG STRUCTURE; ELUTION; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; SOLID; STORAGE TEMPERATURE;

EID: 33746846467     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070600832970     Document Type: Article

References (20)

1. Cutts, S.M.; Nudelman, A.; Rephaeli, A.; Phillips, D.R. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005, 57 (2), 73-81.
2. Saiki, T.; Tsuruo, T.; Sato, W.; Nishikawsa, K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother. Pharmacol. 2005, 56 (supp. 7), 84-89.
3. Dannan, S. A rationale for the development of resistance to adriamycin. Med. Hypoth. 2005, 64 (6), 1238-1239.
4. Tada, Y.; Wada, M.; Migita, T.; Nagayama, J.; Hinoshita, E.; Mochida, Y.; Maehara, Y.; Tsuneyoshi, M.; Kuwano, M.; Michihiko, N. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Intl. J. Cancer 2002, 98 (4), 630-635.
5. Olsufyeva, E.N.; Tevyashova, A.N.; Trestchalin, I.D.; Preobrazhenskaya, M.; Platt, D.; Klyosov, A. Synthesis and antitumor activity of new D-galactose-containing derivatives of doxorubicin. Carbohydr. Res. 2003, 338 (13), 1359-1367.
6. Kakuyama, A.; Sadzuka, Y. Effect of methylxanthine derivatives on doxoru-bicin transport and antitumor activity. Curr. Drug Metabol. 2001, 2 (4), 379-395.
7. Wrudhula, V.M.; Svensson, H.P.; Senter, P.D. Cephalosporiin derivatives of doxorubicin as prodrugs for activatin by monoclonal antibody-beta-lactamase conjugates. J. Med. Chem. 1995, 38 (8), 1380-1385.
8. Nagy, A.; Armalis, P.; Schally, A. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship to daunosamine-modified derivatives of doxorubicin. Proc. Nat. Acad. Sci. U.S.A. 1996, 93 (6), 2464-2469.
9. Dau, D.H.; Duran, G.E.; Sikic, B.I. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. J. Nat. Cancer Inst. 1992, 84 (20), 1587-1592.
10. Chakravarty, P.K.; Carl, P.L.; Weber, M.J.; Datzenellenbogen, J.A. Plasmin activated prodrugs of cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. Chem. 1983, 26 (5), 638-644.
11. Sideratou, Z.; Tsiorvas, D.; Paleos, C.M. Solubilization and release properties of PEGylated diaminobutane poly(propylene imine) dedrimers. J. Coll. Interface Sci. 2001, 242 (1), 272-276.
12. Gershanovish, M.L.; Flov, V.A.; Kotova, D.G.; Stukov, A.N.; Sokolov, L.N.; Ivin, B.A. Multicenter clinical trial of the antitumor drug dioxadet (phase II). Voprosy Onkologii 1998, 44 (2), 216-220.
13. Ohara, M.T.; Sakuda, T.; Cruz, M.; Ferreira, E.; Korolkovas, A. Antimalarial activity of oxidized starch and cellulose imine derivatives. Boilettino Chimico Farmaceutico 1995, 134 (9), 522-527.
14. Hicks, M.B.; Antonucci, V.L.; Riddle, L.; Novak, J.J.; Skrdia, P. Investigations into the chromatographic behavior of a doxorubicin-peptide conjugate. J. Chromatogr. A 2002, 973 (1-2), 27-38.
15. Loadman, P.M.; Calabrese, C.R. Separation methods for anthraquinone related anti-cancer drugs. J. Chromatogr. B Biomed. Sci. Appl. 2001, 764 (1-2), 193-206.
16. Larson, R.R.; Khazaeli, M.B.; Dillon, H.K. Development of an HPLC method for simultaneous analysis of five antineoplastic agents. Appl. Occup. Environ. Hyg. 2003, 18 (2), 109-119.
17. Wei, D.; Mei, Y.; Liu, J. Quantification of doxorubicin and validation of reversal effect of tea polyphenols on multidrug resistance in human carcinoma cells. Biotechnol. Lett. 2003, 25 (4), 291-294.
18. Ahou, Q.; Chowbay, B. Determination of doxorubicin and its metabolites in rat serum and bile by LC: Application to preclinical pharmacokinetic studies. J. Pharm. Biomed. Anal. 2002, 30 (4), 1063-1074.
19. Hansch, C.; Steward, A.R.; Anderson, S.M.; Bentley, D. The parabolic dependence of drug acting upon lipophilic character as revealed by a study of hypnotics. J. Med. Chem. 1998, 11 (1), 1-11.
20. Hansch, C. A quantitative approach to biochemical structure-activity relationships. Acct. Chem. Res. 1969, 2 (8), 232-239.